Evidence map›Paper›PMID 39242318›Full record

ArticleBreast (Edinburgh, Scotland)2024

Neoadjuvant chemotherapy for breast cancer in Italy: A Senonetwork analysis of 37,215 patients treated from 2017 to 2022.

A De Luca, M I Amabile, F Santori, S Di Matteo, M Tomatis, A Ponti, F Frusone, M Taffurelli, C Tinterri, L Marotti and 6 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast (Edinburgh, Scotland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

A De LucaDepartment of Surgery, Sapienza University of Rome, Rome, Italy.
M I AmabileDepartment of Surgery, Sapienza University of Rome, Rome, Italy. Electronic address: mariaida.amabile@uniroma1.it.
F SantoriBreast Center, Azienda Ospedaliera San Giovanni-Addolorata, Rome, Italy; Surgical Residency Program, University of Tor Vergata, Rome, Italy.
S Di MatteoBreast Center, Azienda Ospedaliera San Giovanni-Addolorata, Rome, Italy; Surgical Residency Program, Federico II University, Naples, Italy.
M TomatisAOU Città della Salute e della Scienza, CPO Piemonte and SENONETWORK Data, Warehouse, Turin, Italy.
A PontiAOU Città della Salute e della Scienza, CPO Piemonte and SENONETWORK Data, Warehouse, Turin, Italy.
F FrusoneDepartment of Surgery, Sapienza University of Rome, Rome, Italy.
M TaffurelliIRCCS Policlinico S. Orsola Hospital, University of Bologna, Bologna, Italy.
C TinterriHumanitas Research Hospital and Cancer Center, Breast Surgery, Rozzano, Italy.
L MarottiEusoma, Florence, Italy.
M CalabreseDepartment of Radiology, IRCCS-Ospedale Policlinico San Martino, Genoa, Italy.
C MarchiòDepartment of Medical Sciences, University of Turin, Turin, Italy; Pathology Unit, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.
F PuglisiDepartment of Medicine, University of Udine, Udine, Italy; Department of Medical Oncology, National Cancer Institute, Centro di Riferimento Oncologico (CRO), IRCCS, Aviano, PN, Italy.
I PalumboInternal Medicine and Oncology, Department of Clinical and Experimental Medicine, University of Perugia, Perugia, Italy.
L FortunatoBreast Center, Azienda Ospedaliera San Giovanni-Addolorata, Rome, Italy.
Senonet Collaborative Group*

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdoption of neoadjuvant chemotherapy (NACT) in the "real world" has been poorly investigated. Aim of this study was to examine the rate of NACT in Italy, trends over time and determinants of therapeutic choices.

methodsSenonetwork, the recognized network of Breast Centers in Italy, has developed a voluntary national data warehouse with the aim to monitor and improve treatments quality. A retrospective analysis was conducted among 58,661 breast cancer (BC) patients treated between 2017 and 2022 by 24 high-volume Breast Centers participating in the project.

resultsAfter subset exclusion, 37,215 primary BC patients were analysed, 32,933 underwent primary-breast-surgery and 4,282 underwent NACT. From 2017 to 2022, the overall NACT incidence increased particularly for HR-/HER2+, Triple-Negative, and HR+/HER2+ BC (p < 0.001). In cN + patients the recommendation to axillary lymph-node dissection after NACT decreased over time along with an increase of <4 lymph-nodes removed (p < 0.001). Immediate breast reconstruction and indication for nipple sparing mastectomy increased significantly over time (OR = 1.10, p = 0.011 and OR 1.14, p < 0.001, respectively). On multivariate analysis, there was a trend towards an increased adoption of conservative treatment for HR-/HER2+ (p = 0.01) and Triple Negative tumors (p = 0.06). Implementation of NACT varied significantly among Breast-Centers from 3.8 to 17.7 % (p < 0.001).

conclusionThe impact of NACT on the subsequent surgical management is substantial and continues to evolve over time, resulting in less-extensive surgery. Even among high-volume Centers NACT implementation rate is still highly variable. Although we registered a significant increase in its use during the study period, these results need to be further improved.

Indexed as

Breast NeoplasmsMastectomyNeoadjuvant TherapyAdultAgedChemotherapy, AdjuvantFemaleHumansItalyLymph Node ExcisionMammaplastyMiddle AgedRetrospective StudiesBreast cancerBreast centersNeoadiuvant chemotherapy

Identifiers

PMID39242318
PMCPMC11625020

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.